Trial Outcomes & Findings for Laser Therapy for Treatment of Urogenital Symptoms in Women (NCT NCT03681678)
NCT ID: NCT03681678
Last Updated: 2026-08-17
Results Overview
PGI-I score is recorded 4 weeks after initial treatment completion. The PGI-I asks the patient to "check the box that best describes how your urinary and/or vaginal symptoms are now, compared with how you symptoms were before you began this study." There are 7 possible responses ranging from 1 to 7, where 1 is "Very Much Better", 2 is "Much Better, 3 is "A Little Bit Better", 4 is "No Change", 5 is "A Little Worse", 6 is "Much Worse", and 7 is "Very Much Worse". A score from 1 to 3 would indicate improvement.
COMPLETED
100 participants
4 weeks post-initial treatment
2026-08-17
Participant Flow
Participant milestones
| Measure |
fCO2 Laser Therapy Group
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Overall Study
STARTED
|
100
|
|
Overall Study
Primary Outcome
|
81
|
|
Overall Study
End of study
|
38
|
|
Overall Study
COMPLETED
|
38
|
|
Overall Study
NOT COMPLETED
|
62
|
Reasons for withdrawal
| Measure |
fCO2 Laser Therapy Group
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Overall Study
Lost to Follow-up
|
33
|
|
Overall Study
Withdrawal by Subject
|
16
|
|
Overall Study
Lack of Efficacy
|
4
|
|
Overall Study
Physician Decision
|
1
|
|
Overall Study
Adverse Event
|
1
|
|
Overall Study
Non-compliance
|
4
|
|
Overall Study
Patient received vaginal sling
|
3
|
Baseline Characteristics
Laser Therapy for Treatment of Urogenital Symptoms in Women
Baseline characteristics by cohort
| Measure |
fCO2 Laser Therapy Group
n=100 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=51 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
84 Participants
n=51 Participants
|
|
Age, Categorical
>=65 years
|
16 Participants
n=51 Participants
|
|
Sex: Female, Male
Female
|
100 Participants
n=51 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=51 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=51 Participants
|
|
Race (NIH/OMB)
Asian
|
1 Participants
n=51 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=51 Participants
|
|
Race (NIH/OMB)
Black or African American
|
9 Participants
n=51 Participants
|
|
Race (NIH/OMB)
White
|
90 Participants
n=51 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=51 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=51 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
2 Participants
n=51 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
98 Participants
n=51 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=51 Participants
|
|
Region of Enrollment
United States
|
100 participants
n=51 Participants
|
PRIMARY outcome
Timeframe: 4 weeks post-initial treatmentPGI-I score is recorded 4 weeks after initial treatment completion. The PGI-I asks the patient to "check the box that best describes how your urinary and/or vaginal symptoms are now, compared with how you symptoms were before you began this study." There are 7 possible responses ranging from 1 to 7, where 1 is "Very Much Better", 2 is "Much Better, 3 is "A Little Bit Better", 4 is "No Change", 5 is "A Little Worse", 6 is "Much Worse", and 7 is "Very Much Worse". A score from 1 to 3 would indicate improvement.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=81 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Patient Global Impression of Improvement (PGI-I) Score at 4 Weeks After Initial Treatment
|
2.675 score on a scale
Standard Deviation 0.88
|
SECONDARY outcome
Timeframe: 6 months post-initial treatmentThe average change in patients' PGI-I scores from baseline to 6 months and 36 months post-treatment. The PGI-I asks the patient to "check the one number that best describes how your urinary tract condition is now compared with how it was before your treatment." There are 7 possible responses ranging from 1 to 7, where 1 is "Very Much Better" and 7 is "Very Much Worse". A lower score would represent improvement and a favorable outcome.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=74 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Change in Patient Global Impression of Improvement (PGI-I) Score at 6 Months After Initial Treatment
|
2.91 score on a scale
Standard Deviation 1.09
|
SECONDARY outcome
Timeframe: 6 months post-initial treatmentThe Vaginal Health Inventory Score (VHIS) is an assessment tool, used by providers, to determine if vaginal atrophy is present. Providers perform a vaginal exam and give a score of 1-5 (abnormal to normal, respectively) on each of the following vaginal parameters: elasticity, secretion/fluid volume, vaginal pH, integrity of the epithelium, and lubrication/moisture of the vaginal wall. The total VHIS score is a sum of the individual scores of these 5 vaginal parameters. The minimum score is 5 and the maximum score is 25. A score of 5-14 indicates the presence of vaginal atrophy, while a score of 15-25 indicates normal healthy vaginal tissue. For this outcome measure we reported the change in VHIS between 6 months and baseline. A positive number means that vaginal tissue is healthier at 6 months compared to baseline.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=27 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Change in Vaginal pH and Overall Vaginal Health on Physical Exam as Measured by the Vaginal Health Inventory Score (VHIS) at 6 Months Post-initial Treatment.
|
2.30 score on a scale
Standard Deviation 4.75
|
SECONDARY outcome
Timeframe: 6 months post-initial treatmentThe Questionnaire for Urinary Incontinence Diagnosis (QUID) consists of 2 sections: section 1 are three questions related to stress urinary incontinence (SUI) and section 2 are three questions related to Urge Urinary Incontinence (UUI). This outcome measure is focused on the SUI score only (QUID-SUI). Patients are asked how often they leak urine in three different situations. Responses range from 0 = none of the time, to 5 = all of the time. The total QUID-SUI score ranges from 0 - 15, with a higher score meaning more frequent urinary leakage in response to a stress event (e.g. cough, lifting, exercise). Here we report the change in QUID-SUI score from 6 months to baseline. A negative number means the QUID stress urinary incontinence score has gone down and severity of SUI his better at 6 months compared to baseline.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=66 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Change in Urinary Symptoms Specifically Stress Urinary Incontinence Score as Measured by the Questionnaire for Urinary Incontinence Diagnosis (QUID) at 6 Months Post-initial Treatment.
|
-1.03 score on a scale
Standard Deviation 2.33
|
SECONDARY outcome
Timeframe: 6 months post-initial treatmentFor this outcome measure, we used the OAB-q SF, which consists of two scales assessing symptom bother and health-related quality of life (HR-QOL) in patients with OAB. In this outcome measure we specifically look at the symptom bother scale that consists of 6 questions. Each question asks about the level of bother related to a specific symptom (e.g. urgency, frequency, nighttime urination and leakage). The patient rates the degree of bother on a 6-point scale with 1 = Not at all and 6 = A very great deal. The scores of the 6 questions are added and converted to a 100-point scale. The symptom bother score ranges from 0-100. A higher score is associated with a high degree of bother. For this outcome measure, we report the change in the mean symptom bother scale from 6 months to baseline. A negative change means that the degree of symptom bother decreased at 6 months compared to before treatment.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=66 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Change in Overactive Bladder (OAB) Symptoms, Specifically Symptom Bother as Measured by the Overactive Bladder Questionnaire-Short Form (OAB-q SF) at 6 Months After Initial Treatment.
|
-12.63 score on a scale
Standard Deviation 19.07
|
SECONDARY outcome
Timeframe: 6 months post-initial treatmentA 3-day voiding diary will be completed by the patient and evaluated to describe urinary frequency (number of voids) and incontinence episodes. The change in number of voids over a 3 day period at 6 months minus baseline will be measured. A negative number means the number of voids went down compared to baseline.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=65 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Change in Number of Voids as Recorded on Voiding Diary at 6 Months Post-initial Treatment.
|
-1.85 number of voids
Standard Deviation 4.49
|
SECONDARY outcome
Timeframe: 6 months post-initial treatmentThe FSFI consists of 6 subscales related to sexual desire (2 Qs scale 1 worst - 5 best), arousal (4Qs 0 worst - 5 best), lubrication (4Qs 0 worst-5 best), orgasm (3Qs 0 worst - 5 best), satisfaction ( 3Qs 0 worst - 5 best), and pain (3 Qs 0 worst - 5 best). Higher scores indicate higher sexual functioning. Scores range from 2-36. A score of 26.55 has been clinically selected as the cut-off for sexual dysfunction. Scores below this value indicate sexual dysfunction. The overall change is measured at 6 months minus baseline. A positive score means the sexual dysfunction symptoms are getting worse. Only people that had sexual activity were included.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=17 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Change in Sexual Function, Including Dyspareunia Symptoms, as Measured by the Female Sexual Function Inventory (FSFI) at 6 Months Post-initial Treatment.
|
4.97 score on a scale
Standard Deviation 5.25
|
SECONDARY outcome
Timeframe: 6 months post-initial treatmentPopulation: Participants analyzed included only those that reported a history of 4 or more positive urine cultures in a year at baseline.
A clean catch urine specimen will be collected at each visit. A positive urine dipstick test will have the presence of leukocytes and nitrites accompanied by symptoms (dysuria, bladder pain, and/or urinary frequency) and will be sent for a culture. A positive urine culture has the presence of bacterial growth. Only patients that reported recurrent UTI's - 4 or more in the past year (i.e. had 4 or more positive urine cultures in a year) at baseline with an occurrence of a positive urine culture at or before 6 months post-initial treatment will be counted.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=13 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Frequency of Urinary Tract Infection (UTI) Occurrences, as Measured by a Positive Urine Culture Test at 6 Months Post-initial Treatment.
|
3 total number of positive urine cultures
|
SECONDARY outcome
Timeframe: 6 months post-initial treatmentThe GAD-7 is a self-reported questionnaire for screening and measuring severity of generalized anxiety disorder. There are 7 questions total asking how often the patient has been bothered by certain problems over the past 2 weeks. Each answer is scored on a scale from 0 = not at all to 3 = nearly every day. All scores are added up to calculate the total score which ranges from 0 - 21. Total scores greater than or equal to 10 indicate moderate anxiety and further assessment is recommended. In this outcome measure we report the change in GAD-7 score between 6 months and baseline. A negative number means a reduction in GAD-7 score and therefore a reduction in anxiety/depression at 6 months compared to before treatment.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=66 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Change in Mental Health Status as Measured by the Generalized Anxiety Disorder Questionnaire (GAD-7) at 6 Months Post-initial Treatment.
|
-0.09 score on a scale
Standard Deviation 4.14
|
SECONDARY outcome
Timeframe: 6 months post-initial treatmentThe PHQ-8 is an eight-item questionnaire that measures the severity of depression symptoms over the past 2 weeks. For each of the questions, the patient is asked the rate how often they are bothered by a specific problem (e.g. sleep disturbance, fatigue, appetite change, low-self esteem, poor concentration). Each question is scored from 0 = not at all to 3 = nearly every day. The scores of each question are added together to form the total score, which ranges from 0 - 24. The higher the score, the more severe depressive symptoms are. A score of 10 or greater is commonly used to indicate the presence of clinically significant depressive symptoms. Here we report the change in score between 6 months and baseline. A negative number means there is a reduction in PHQ8 score at 6 months compared to before treatment and therefore a reduction in depression.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=65 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Change in Mental Health Status as Measured by the Patient Health Questionnaire (PHQ-8) at 6 Months Post-initial Treatment.
|
-0.62 score on a scale
Standard Deviation 4.26
|
SECONDARY outcome
Timeframe: 6 months post-initial treatmentThe Incontinence Quality of Life Questionnaire (I-QOL) is a validated tool to assess the impact of urinary incontinence problems. The I-QOL has 22 incontinent-specific quality of life items. The 22 items are broken down into 3 subscales: Avoidance and Limiting Behaviors Score (8 of the 22 items), Psychosocial Impacts Score (9 of the 22 items), and Social Embarrassment Score (5 of the 22 items). Each question has a five-point ordinal response scale: 1= Extremely, 2= Quite a Bit, 3= Moderately, 4= A Little, and 5= Not at All. All 22 items are summed up, and the sum is converted to a 100-point scale. The range of the score is 0-100, with a high score indicating a better quality of life. In this outcome measure we report the change in the I-QOL score at 6 months minus the score at baseline. A positive score indicates that the quality of life improved at 6 months compared to before treatment.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=66 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Change in Life and Sexual Impact of Vulvovaginal Skin Symptoms as Measured by the Incontinence Quality of Life Questionnaire (I-QOL) at 6 Months.
|
8.25 score on a scale
Standard Deviation 14.74
|
SECONDARY outcome
Timeframe: 6 months post-initial treatmentA vaginal exam is completed at 6 months. In some cases the 6 month visit was completed remotely and thus a vaginal exam was not completed. Presence or absence of lactobacillus will be collected by the physician via a vaginal swab and assessed under the microscope of the patients that had a vaginal exam completed. This is the total number of patients positive for lactobacillus at 6 months.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=27 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
The Presence of Lactobacillus, Assessed by Vaginal Swab at 6 Months.
|
6 Participants
|
SECONDARY outcome
Timeframe: 36 months post-initial treatmentThe average change in patients' PGI-I scores from baseline to 6 months and 36 months post-treatment. The PGI-I asks the patient to "check the one number that best describes how your urinary tract condition is now compared with how it was before your treatment." There are 7 possible responses ranging from 1 to 7, where 1 is "Very Much Better" and 7 is "Very Much Worse". A lower score would represent improvement and a favorable outcome.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=38 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Change in Patient Global Impression of Improvement (PGI-I) Score at 36 Months.
|
2.74 score on a scale
Standard Deviation 1.43
|
SECONDARY outcome
Timeframe: 36 months post-initial treatmentThe Vaginal Health Inventory Score (VHIS) is an assessment tool, used by providers, to determine if vaginal atrophy is present. Providers perform a vaginal exam and give a score of 1-5 (abnormal to normal, respectively) on each of the following vaginal parameters: elasticity, secretion/fluid volume, vaginal pH, integrity of the epithelium, and lubrication/moisture of the vaginal wall. The total VHIS score is a sum of the individual scores of these 5 vaginal parameters. The scale ranges from 5-25. A score of 5-14 indicates the presence of vaginal atrophy, while a score of 15-25 indicates normal/healthy vaginal tissue. For this outcome measure we reported the change in VHIS between 36 months and baseline. A positive number means that vaginal tissue is healthier at 36 months compared to baseline.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=35 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Change in Vaginal pH and Overall Vaginal Health on Physical Exam as Measured by the Vaginal Health Inventory Score (VHIS) at 36 Month Post-initial Treatment.
|
0.77 score on a scale
Standard Deviation 4.41
|
SECONDARY outcome
Timeframe: 36 months post-initial treatmentThe Questionnaire for Urinary Incontinence Diagnosis (QUID) consists of 2 sections: section 1 are three questions related to stress urinary incontinence (SUI) and section 2 are three questions related to Urge Urinary Incontinence (UUI). This outcome measure is focused on the SUI score only (QUID-SUI). Patients are asked how often they leak urine in three different situations. Responses range from 0 = none of the time, to 5 = all of the time. The total QUID-SUI score ranges from 0 - 15, with a higher score meaning more frequent urinary leakage in response to a stress event (e.g. cough, lifting, exercise). Here we report the change in QUID-SUI score from 36 months to baseline. A negative number means the QUID stress urinary incontinence score has gone down and severity of SUI his better at 36 months compared to baseline.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=38 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Change in Urinary Symptoms, Specifically Stress Urinary Incontinence as Measured by the Questionnaire for Urinary Incontinence Diagnosis (QUID) at 36 Months Post-inital Treatment.
|
-1.5 score on a scale
Standard Deviation 2.84
|
SECONDARY outcome
Timeframe: 6 months post-initial treatmentThe Questionnaire for Urinary Incontinence Diagnosis (QUID) consists of 2 sections: section 1 are three questions related to stress urinary incontinence (SUI) and section 2 are three questions related to Urge Urinary Incontinence (UUI). This outcome measure is focused on the UUI score only (QUID-UUI). Patients are asked how often they leak urine in three different situations related to urgency. Responses range from 0 = none of the time, to 5 = all of the time. The total QUID-UUI score ranges from 0 - 15, with a higher score meaning more frequent urinary leakage due to urgency. Here we report the change in QUID-UUI score from 6 months to baseline. A negative number means the QUID urge urinary incontinence score has gone down and severity of UUI has improved at 6 months compared to before treatment.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=67 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Change in Urinary Symptoms Specifically Urge Urinary Incontinence Score as Measured by the Questionnaire for Urinary Incontinence Diagnosis (QUID) at 6 Months Post-initial Treatment.
|
-1.54 score on a scale
Standard Deviation 3.33
|
SECONDARY outcome
Timeframe: 36 months post-initial treatmentThe Questionnaire for Urinary Incontinence Diagnosis (QUID) consists of 2 sections: section 1 are three questions related to stress urinary incontinence (SUI) and section 2 are three questions related to Urge Urinary Incontinence (UUI). This outcome measure is focused on the UUI score only (QUID-UUI). Patients are asked how often they leak urine in three different situations related to urgency. Responses range from 0 = none of the time, to 5 = all of the time. The total QUID-UUI score ranges from 0 - 15, with a higher score meaning more frequent urinary leakage due to urgency. Here we report the change in QUID-UUI score from 36 months to baseline. A negative number means the QUID urge urinary incontinence score has gone down and severity of UUI has improved at 36 months compared to before treatment.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=38 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Change in Urinary Symptoms Specifically Urge Urinary Incontinence Score as Measured by the Questionnaire for Urinary Incontinence Diagnosis (QUID) at 36 Months Post-initial Treatment.
|
-1.39 score on a scale
Standard Deviation 2.48
|
SECONDARY outcome
Timeframe: 36 months post-initial treatmentFor this outcome measure, we used the OAB-q SF, which consists of two scales assessing symptom bother and health-related quality of life (HR-QOL) in patients with OAB. In this outcome measure we specifically look at the health-related quality of life (HR-QOL) scale that consists of 13 questions. Each question asks how the patient's quality of life has been impacted. The patient rates the degree of impact on a 6-point scale with 1 = Not at all and 6 = A very great deal. The scores of the 13 questions are added and converted to a 100-point scale. The HR-QOL score ranges from 0-100. A higher score is associated with a better quality of life. For this outcome measure, we report the change in the mean HR-QOL score for 36 months minus baseline. A positive change means that the quality of life became better by 36 months as compared to before treatment.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=38 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Change in Overactive Bladder (OAB) Symptoms, Specifically Health-related Quality of Life (HR-QOL) as Measured by the Overactive Bladder Questionnaire-Short Form (OAB-q SF) at 36 Months Post-initial Treatment.
|
7.77 score on a scale
Standard Deviation 17.82
|
SECONDARY outcome
Timeframe: 36 months post-initial treatmentFor this outcome measure, we used the OAB-q SF, which consists of two scales assessing symptom bother and health-related quality of life (HR-QOL) in patients with OAB. In this outcome measure we specifically look at the symptom bother scale that consists of 6 questions. Each question asks about the level of bother related to a specific symptom (e.g. urgency, frequency, nighttime urination and leakage). The patient rates the degree of bother on a 6-point scale with 1 = Not at all and 6 = A very great deal. The scores of the 6 questions are added and converted to a 100-point scale. The symptom bother score ranges from 0-100. A higher score is associated with a high degree of bother. For this outcome measure, we report the change in the mean symptom bother scale from 36 months to baseline. A negative change means that the degree of symptom bother decreased at 36 months compared to before treatment.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=38 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Change in Overactive Bladder (OAB) Symptoms, Specifically Symptom Bother as Measured by the Overactive Bladder Questionnaire-Short Form (OAB-q SF) at 36 Months Post-initial Treatment.
|
-13.16 score on a scale
Standard Deviation 22.34
|
SECONDARY outcome
Timeframe: 6 months post-initial treatmentFor this outcome measure, we used the OAB-q SF, which consists of two scales assessing symptom bother and health-related quality of life (HR-QOL) in patients with OAB. In this outcome measure we specifically look at the health-related quality of life (HR-QOL) scale that consists of 13 questions. Each question asks how the patient's quality of life has been impacted. The patient rates the degree of impact on a 6-point scale with 1 = Not at all and 6 = A very great deal. The scores of the 13 questions are added and converted to a 100-point scale. The HR-QOL score ranges from 0-100. A higher score is associated with a better quality of life. For this outcome measure, we report the change in the mean HR-QOL score for 6 months minus baseline. A positive change means that the quality of life became better by 6 months as compared to before treatment.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=66 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Change in Overactive Bladder (OAB) Symptoms, Specifically Health-related Quality of Life (HR-QOL) as Measured by the Overactive Bladder Questionnaire-Short Form (OAB-q SF) at 6 Months Post-initial Treatment.
|
9.60 score on a scale
Standard Deviation 15.45
|
SECONDARY outcome
Timeframe: 36 months post-initial treatmentA 3-day voiding diary will be completed by the patient and evaluated to describe urinary frequency (number of voids) and incontinence episodes. The change in number of voids over a 3 day period at 36 months minus baseline will be measured. A negative number means the number of voids went down compared to baseline.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=38 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Change in Number of Voids as Recorded on Voiding Diary at 36 Months Post-initial Treatment.
|
-3.05 number of voids
Standard Deviation 6.20
|
SECONDARY outcome
Timeframe: 6 months post-initial treatmentA 3-day voiding diary will be completed by the patient and evaluated to describe incontinence episodes (number of stress urinary incontinence occurrences). The change in number of stress urinary incontinence episodes over a 3 day period at 6 months minus baseline will be measured. A negative number means the number of stress urinary incontinence events went down compared to baseline.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=66 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Change in Number of Stress Urinary Incontinence Events as Recorded on Voiding Diary at 6 Months Post-initial Treatment.
|
-0.26 number of stress incontinence events
Standard Deviation 4.49
|
SECONDARY outcome
Timeframe: 36 months post-initial treatmentA 3-day voiding diary will be completed by the patient and evaluated to describe incontinence episodes (number of stress urinary incontinence occurrences). The change in number of stress urinary incontinence episodes over a 3 day period at 36 months minus baseline will be measured. A negative number means the number of stress urinary incontinence events went down compared to baseline.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=38 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Change in Number of Stress Urinary Incontinence Events as Recorded on Voiding Diary at 36 Months Post-initial Treatment.
|
-1.03 number of stress incontinence events
Standard Deviation 3.82
|
SECONDARY outcome
Timeframe: 6 months post-initial treatmentA 3-day voiding diary will be completed by the patient and evaluated to describe incontinence episodes (number of urge urinary incontinence events). The change in number of urge urinary incontinence events over a 3 day period at 6 months minus baseline will be measured. A negative number means the number of urge urinary incontinence events went down compared to baseline.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=66 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Change in Number of Urge Urinary Incontinence Events as Recorded on Voiding Diary at 6 Months Post-initial Treatment.
|
-1.11 number of stress incontinence events
Standard Deviation 5.45
|
SECONDARY outcome
Timeframe: 36 months post-initial treatmentA 3-day voiding diary will be completed by the patient and evaluated to describe incontinence episodes (number of urge urinary incontinence events). The change in number of urge urinary incontinence events over a 3 day period at 36 months minus baseline will be measured. A negative number means the number of urge urinary incontinence events went down compared to baseline.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=38 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Change in Number of Urge Urinary Incontinence Events as Recorded on Voiding Diary at 36 Months Post-initial Treatment.
|
-1.11 number of stress incontinence events
Standard Deviation 4.43
|
SECONDARY outcome
Timeframe: 36 months post-initial treatmentThe GAD-7 is a self-reported questionnaire for screening and measuring severity of generalized anxiety disorder. There are 7 questions total asking how often the patient has been bothered by certain problems over the past 2 weeks. Each answer is scored on a scale from 0 = not at all to 3 = nearly every day. All scores are added up to calculate the total score which ranges from 0 - 21. Total scores greater than or equal to 10 indicate moderate anxiety and further assessment is recommended. In this outcome measure we report the change in GAD-7 score between 36 months and baseline. A negative number means a reduction in GAD-7 score and therefore a reduction in anxiety/depression at 36 months compared to before treatment.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=38 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Change in Mental Health Status as Measured by the Generalized Anxiety Disorder Questionnaire (GAD-7) at 36 Months Post-initial Treatment.
|
-1.34 score on a scale
Standard Deviation 4.47
|
SECONDARY outcome
Timeframe: 36 months post-initial treatmentThe PHQ-8 is an eight-item questionnaire that measures the severity of depression symptoms over the past 2 weeks. For each of the questions, the patient is asked the rate how often they are bothered by a specific problem (e.g. sleep disturbance, fatigue, appetite change, low-self esteem, poor concentration). Each question is scored from 0 = not at all to 3 = nearly every day. The scores of each question are added together to form the total score, which ranges from 0 - 24. The higher the score, the more severe depressive symptoms are. A score of 10 or greater is commonly used to indicate the presence of clinically significant depressive symptoms. Here we report the change in score between 36 months and baseline. A negative number means there is a reduction in PHQ8 score at 36 months compared to before treatment and therefore a reduction in depression.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=38 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Change in Mental Health Status as Measured by the Patient Health Questionnaire (PHQ-8) at 36 Months Post-initial Treatment.
|
-0.63 score on a scale
Standard Deviation 4.20
|
SECONDARY outcome
Timeframe: 36 months post-initial treatmentThe FSFI consists of 6 subscales related to sexual desire (2 Qs scale 1 worst - 5 best), arousal (4Qs 0 worst - 5 best), lubrication (4Qs 0 worst-5 best), orgasm (3Qs 0 worst - 5 best), satisfaction ( 3Qs 0 worst - 5 best), and pain (3 Qs 0 worst - 5 best). Higher scores indicate higher sexual functioning. Scores range from 2-36. A score of 26.55 has been clinically selected as the cut-off for sexual dysfunction. Scores below this value indicate sexual dysfunction. The change is measured as the difference at 36 months minus baseline. A positive score means the sexual dysfunction symptoms are getting worse. Only people that had sexual activity were included.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=16 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Change in Sexual Function, Including Dyspareunia Symptoms, as Measured by the Female Sexual Function Inventory (FSFI) at 36 Months Post-initial Treatment.
|
5.82 score on a scale
Standard Deviation 4.26
|
SECONDARY outcome
Timeframe: 36 months post-initial treatmentPopulation: Participants analyzed included only those that reported a history of 4 or more positive urine cultures in a year at baseline.
A clean catch urine specimen will be collected at each visit. A positive urine dipstick test will have the presence of leukocytes and nitrites accompanied by symptoms (dysuria, bladder pain, and/or urinary frequency) and will be sent for a culture. A positive urine culture has the presence of bacterial growth. Only patients that reported recurrent UTI's - 4 or more in the past year (i.e. had 4 or more positive urine cultures in a year) at baseline with an occurrence of a positive urine culture after 6 months but before or at 36 months post-initial treatment will be counted.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=13 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Frequency of Urinary Tract Infection (UTI) Occurrences, as Measured by a Positive Urine Culture Test at 36 Months Post-initial Treatment.
|
3 total number of positive urine cultures
|
SECONDARY outcome
Timeframe: 36 months post-initial treatmentA vaginal exam is completed at 36 months. In some cases the 36 month visit was completed remotely and thus a vaginal exam was not completed. Presence or absence of lactobacillus will be collected by the physician via a vaginal swab and assessed under the microscope of the patients that had a vaginal exam completed. This is the total number of patients positive for lactobacillus at 36 months.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=35 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
The Presence of Lactobacillus, Assessed by Vaginal Swab at 36 Months.
|
3 Participants
|
SECONDARY outcome
Timeframe: 36 months post-initial treatmentThe Incontinence Quality of Life Questionnaire (I-QOL) is a validated tool to assess the impact of urinary incontinence problems. The I-QOL has 22 incontinent-specific quality of life items all having the following five-point ordinal response scale: 1= Extremely, 2= Quite a Bit, 3= Moderately, 4= A Little, and 5= Not at All. All 22 items are summed up, and the sum is converted to a 100-point scale. The range of the score is 0-100, with a high score indicating a better quality of life. In this outcome measure we report the change in the I-QOL score at 36 months minus the score at baseline. A positive score indicates that the quality of life improved at 36 months compared to before treatment.
Outcome measures
| Measure |
fCO2 Laser Therapy Group
n=38 Participants
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Change in Life and Sexual Impact of Vulvovaginal Skin Symptoms as Measured by the Incontinence Quality of Life Questionnaire (I-QOL) at 36 Months.
|
8.68 score on a scale
Standard Deviation 13.78
|
Adverse Events
fCO2 Laser Therapy Group
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
fCO2 Laser Therapy Group
n=81 participants at risk
Women treated with the fCO2 laser
fCO2 Laser Therapy Group: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
|
|---|---|
|
Nervous system disorders
Pudendal nerve pain
|
1.2%
1/81 • Number of events 1 • 3 years
|
|
Reproductive system and breast disorders
Vaginal bleeding
|
11.1%
9/81 • Number of events 10 • 3 years
|
|
Infections and infestations
Urinary Tract Infection
|
11.1%
9/81 • Number of events 13 • 3 years
|
|
Reproductive system and breast disorders
vaginal pain
|
2.5%
2/81 • Number of events 2 • 3 years
|
|
Infections and infestations
Vaginal yeast infection
|
4.9%
4/81 • Number of events 4 • 3 years
|
|
Reproductive system and breast disorders
Vaginal Burning
|
2.5%
2/81 • Number of events 3 • 3 years
|
|
Renal and urinary disorders
Urethral mass
|
1.2%
1/81 • Number of events 1 • 3 years
|
|
Renal and urinary disorders
Bladder pressure
|
1.2%
1/81 • Number of events 1 • 3 years
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
1.2%
1/81 • Number of events 1 • 3 years
|
|
Renal and urinary disorders
Dysuria
|
2.5%
2/81 • Number of events 2 • 3 years
|
|
Renal and urinary disorders
Increase urinary urgency
|
4.9%
4/81 • Number of events 4 • 3 years
|
|
Reproductive system and breast disorders
Vaginal infection - not specified
|
1.2%
1/81 • Number of events 1 • 3 years
|
|
Reproductive system and breast disorders
ovarian cysts
|
1.2%
1/81 • Number of events 1 • 3 years
|
|
Renal and urinary disorders
positive urine dipstick
|
1.2%
1/81 • Number of events 2 • 3 years
|
|
Infections and infestations
Bacterial vaginosis
|
7.4%
6/81 • Number of events 7 • 3 years
|
|
Injury, poisoning and procedural complications
Pain during treatment
|
4.9%
4/81 • Number of events 5 • 3 years
|
|
Renal and urinary disorders
Suspected urinary calculus
|
1.2%
1/81 • Number of events 1 • 3 years
|
|
Infections and infestations
Suspected bacterial vaginosis
|
1.2%
1/81 • Number of events 1 • 3 years
|
|
Injury, poisoning and procedural complications
Discomfort with probe insertion
|
4.9%
4/81 • Number of events 4 • 3 years
|
|
Reproductive system and breast disorders
Vaginal burning during treatment
|
6.2%
5/81 • Number of events 5 • 3 years
|
|
Musculoskeletal and connective tissue disorders
Flare of pelvic floor muscle
|
1.2%
1/81 • Number of events 3 • 3 years
|
|
Skin and subcutaneous tissue disorders
Rash - Allergic reaction to Cipro
|
1.2%
1/81 • Number of events 1 • 3 years
|
|
Reproductive system and breast disorders
Worsening dyspareunia
|
1.2%
1/81 • Number of events 1 • 3 years
|
|
Reproductive system and breast disorders
Vaginal itching
|
3.7%
3/81 • Number of events 4 • 3 years
|
|
Reproductive system and breast disorders
Vaginal irritation
|
1.2%
1/81 • Number of events 1 • 3 years
|
|
Nervous system disorders
Numbness to lower extremity and buttock
|
1.2%
1/81 • Number of events 2 • 3 years
|
|
Reproductive system and breast disorders
Exacerbation of vaginal atrophy
|
1.2%
1/81 • Number of events 1 • 3 years
|
|
Skin and subcutaneous tissue disorders
Left labial itching and redness
|
1.2%
1/81 • Number of events 1 • 3 years
|
|
Injury, poisoning and procedural complications
Trauma to introitus during treatment
|
1.2%
1/81 • Number of events 1 • 3 years
|
|
Renal and urinary disorders
Proteinuria
|
1.2%
1/81 • Number of events 1 • 3 years
|
|
Skin and subcutaneous tissue disorders
Post treatment itching and irritation
|
1.2%
1/81 • Number of events 1 • 3 years
|
|
Reproductive system and breast disorders
vaginal discomfort during treatment
|
1.2%
1/81 • Number of events 1 • 3 years
|
|
Surgical and medical procedures
Pudendal Interstim revision
|
1.2%
1/81 • Number of events 1 • 3 years
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place